Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lilly

Eli Lilly HQ

Lilly sinks as solanezumab fails again in Alzheimer’s

Amyloid-targeting drug showed no significant evidence of slow in cognitive decline

Eli Lilly HQ

Lilly bags EU approval for cancer treatment Lartruvo

Licensed for use with doxorubicin for soft tissue sarcoma patients

Eli Lilly HQ

Lilly promises solanezumab news in Alzheimer’s ‘before year-end’

If anti-amyloid drug proves effective, sales could reach $7.5bn according to analysts

- PMLiVE

At current progress, 2025 Alzheimer’s target ‘unlikely to be reached’

Drug development and diagnosis process requires shake-up to create effective therapies

- PMLiVE

Lundbeck trial failure dashes hopes in Alzheimer’s once again

Phase III trial fails to substantially improve cognition despite promising phase II data

- PMLiVE

Alzheimer’s disease: reviewing the immediate treatment horizon

Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to patients with Alzheimer's disease.

Blue Latitude Health

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

FDA approves Lilly-backed Bluetooth insulin device

Clears Companion Medical’s Bluetooth-enabled pen and smartphone app

Lilly promotes Joshua Smiley to new finance role

He will replace Thomas Grein, who is retiring in next month

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

- PMLiVE

Tau protein drug fails late-stage trial

Alzheimer’s disease therapy only showed benefit in patients with no existing treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links